Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety Study of Autologous T Cells Engineered to Target CD19 and CRISPR Gene Edited to Eliminate Endogenous HPK1 (XYF19 CAR-T Cells) for Relapsed or Refractory Haematopoietic Malignancies.

NCT04037566 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT04037566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04037566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety Study of Autologous T Cells Engineered to Target CD19 and CRISPR Gene Edited to Eliminate Endogenous HPK1 (XYF19 CAR-T Cells) for Relapsed or Refractory Haematopoietic Malignancies.
Lead sponsor
Xijing Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
August 31, 2019
Completion date
August 31, 2024
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cd19 positive, leukemia lymphocytic acute (all) in relapse, leukemia lymphocytic acute (all) refractory, lymphoma, b-cell